| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.1 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.046 | 0.1 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.1 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |